Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However,...
Gespeichert in:
Veröffentlicht in: | Modern pathology 2022-10, Vol.35 (10), p.1411-1422 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1422 |
---|---|
container_issue | 10 |
container_start_page | 1411 |
container_title | Modern pathology |
container_volume | 35 |
creator | Gisriel, Savanah D. Yuan, Ji Braunberger, Ryan C. Maracaja, Danielle L.V. Chen, Xueyan Wu, Xiaojun McCracken, Jenna Chen, Mingyi Xie, Yi Brown, Laura E. Li, Peng Zhou, Yi Sethi, Tarsheen McHenry, Austin Hauser, Ronald G. Paulson, Nathan Tang, Haiming Hsi, Eric D. Wang, Endi Zhang, Qian-Yun Young, Ken H. Xu, Mina L. Pan, Zenggang |
description | Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature. |
doi_str_mv | 10.1038/s41379-022-01091-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9926946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395222002563</els_id><sourcerecordid>2664806804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhSMEokPhD7BAltiwCdh52ghVggooUiU2sLZubm4mrhJ7sJ2hs-WX4yGlPBZdWfL9zvE9Pln2VPCXgpfyVahE2aqcF0XOBVciv76XbURd8nQl6_vZhktV5qWqi5PsUQhXnIuqlsXD7KSs66ZI6k3242KZwbKR_I7C3vglMJlb2kI0e2I0DEswzuYdBOrZBH5L7F2ONE1sOsy70c3wmgHrTYjGYmRko4kH9t3EkS3WfFuI4WSsQbeDOLrJbQ0yHMEDRvJHFYbH2YMBpkBPbs7T7OuH91_OL_LLzx8_nb-9zLEu2pgLPqQ4opEddBJlW0NVNkDUCgRVK970UgLyXkkYKqz6FlupBGAHqIam4-Vpdrb67pZuph7Trh4mvfNmBn_QDoz-d2LNqLdur5UqGlU1yeDFjYF3KVmIejbh-BdgyS1BF01TSd5IXiX0-X_olVu8TfF00QqZsFYeqWKl0LsQPA23ywiujxXrtWKdKta_KtbXSfTs7xi3kt-dJqBcgZBGdkv-z9t32r5ZVZQq2JukCmjIIvXGE0bdO3OX_CeGEMou</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718480784</pqid></control><display><type>article</type><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</creator><creatorcontrib>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</creatorcontrib><description>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/s41379-022-01091-x</identifier><identifier>PMID: 35562413</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>13/1 ; 13/51 ; 38/32 ; 631/67/1990/291/1621/1915 ; 692/699/1541/1990/291/1621/1915 ; Aged ; Aged, 80 and over ; B-cell lymphoma ; Case reports ; CD20 antigen ; Chemotherapy ; Effusion ; Epstein-Barr virus ; Epstein-Barr Virus Infections - complications ; Herpesviridae Infections - complications ; Herpesvirus 4, Human ; Herpesvirus 8, Human ; HIV ; Human immunodeficiency virus ; Humans ; Laboratory Medicine ; Lymphocytes B ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Primary Effusion - diagnosis ; Lymphoma, Primary Effusion - pathology ; Medical prognosis ; Medicine ; Medicine & Public Health ; Myc protein ; Pathology ; Pax5 protein ; Pleural cavity ; Primary effusion lymphoma ; Retrospective Studies ; Rituximab ; Targeted cancer therapy</subject><ispartof>Modern pathology, 2022-10, Vol.35 (10), p.1411-1422</ispartof><rights>2022 United States & Canadian Academy of Pathology</rights><rights>The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2022</rights><rights>2022. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.</rights><rights>The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</citedby><cites>FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</cites><orcidid>0000-0001-8623-4067 ; 0000-0002-9012-6680 ; 0000-0001-6754-0480 ; 0000-0003-0217-1789 ; 0000-0002-5755-8932 ; 0000-0002-7361-7162 ; 0000-0001-9513-245X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35562413$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gisriel, Savanah D.</creatorcontrib><creatorcontrib>Yuan, Ji</creatorcontrib><creatorcontrib>Braunberger, Ryan C.</creatorcontrib><creatorcontrib>Maracaja, Danielle L.V.</creatorcontrib><creatorcontrib>Chen, Xueyan</creatorcontrib><creatorcontrib>Wu, Xiaojun</creatorcontrib><creatorcontrib>McCracken, Jenna</creatorcontrib><creatorcontrib>Chen, Mingyi</creatorcontrib><creatorcontrib>Xie, Yi</creatorcontrib><creatorcontrib>Brown, Laura E.</creatorcontrib><creatorcontrib>Li, Peng</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Sethi, Tarsheen</creatorcontrib><creatorcontrib>McHenry, Austin</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><creatorcontrib>Paulson, Nathan</creatorcontrib><creatorcontrib>Tang, Haiming</creatorcontrib><creatorcontrib>Hsi, Eric D.</creatorcontrib><creatorcontrib>Wang, Endi</creatorcontrib><creatorcontrib>Zhang, Qian-Yun</creatorcontrib><creatorcontrib>Young, Ken H.</creatorcontrib><creatorcontrib>Xu, Mina L.</creatorcontrib><creatorcontrib>Pan, Zenggang</creatorcontrib><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</description><subject>13/1</subject><subject>13/51</subject><subject>38/32</subject><subject>631/67/1990/291/1621/1915</subject><subject>692/699/1541/1990/291/1621/1915</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>B-cell lymphoma</subject><subject>Case reports</subject><subject>CD20 antigen</subject><subject>Chemotherapy</subject><subject>Effusion</subject><subject>Epstein-Barr virus</subject><subject>Epstein-Barr Virus Infections - complications</subject><subject>Herpesviridae Infections - complications</subject><subject>Herpesvirus 4, Human</subject><subject>Herpesvirus 8, Human</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Laboratory Medicine</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Primary Effusion - diagnosis</subject><subject>Lymphoma, Primary Effusion - pathology</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Myc protein</subject><subject>Pathology</subject><subject>Pax5 protein</subject><subject>Pleural cavity</subject><subject>Primary effusion lymphoma</subject><subject>Retrospective Studies</subject><subject>Rituximab</subject><subject>Targeted cancer therapy</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtv1DAUhSMEokPhD7BAltiwCdh52ghVggooUiU2sLZubm4mrhJ7sJ2hs-WX4yGlPBZdWfL9zvE9Pln2VPCXgpfyVahE2aqcF0XOBVciv76XbURd8nQl6_vZhktV5qWqi5PsUQhXnIuqlsXD7KSs66ZI6k3242KZwbKR_I7C3vglMJlb2kI0e2I0DEswzuYdBOrZBH5L7F2ONE1sOsy70c3wmgHrTYjGYmRko4kH9t3EkS3WfFuI4WSsQbeDOLrJbQ0yHMEDRvJHFYbH2YMBpkBPbs7T7OuH91_OL_LLzx8_nb-9zLEu2pgLPqQ4opEddBJlW0NVNkDUCgRVK970UgLyXkkYKqz6FlupBGAHqIam4-Vpdrb67pZuph7Trh4mvfNmBn_QDoz-d2LNqLdur5UqGlU1yeDFjYF3KVmIejbh-BdgyS1BF01TSd5IXiX0-X_olVu8TfF00QqZsFYeqWKl0LsQPA23ywiujxXrtWKdKta_KtbXSfTs7xi3kt-dJqBcgZBGdkv-z9t32r5ZVZQq2JukCmjIIvXGE0bdO3OX_CeGEMou</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Gisriel, Savanah D.</creator><creator>Yuan, Ji</creator><creator>Braunberger, Ryan C.</creator><creator>Maracaja, Danielle L.V.</creator><creator>Chen, Xueyan</creator><creator>Wu, Xiaojun</creator><creator>McCracken, Jenna</creator><creator>Chen, Mingyi</creator><creator>Xie, Yi</creator><creator>Brown, Laura E.</creator><creator>Li, Peng</creator><creator>Zhou, Yi</creator><creator>Sethi, Tarsheen</creator><creator>McHenry, Austin</creator><creator>Hauser, Ronald G.</creator><creator>Paulson, Nathan</creator><creator>Tang, Haiming</creator><creator>Hsi, Eric D.</creator><creator>Wang, Endi</creator><creator>Zhang, Qian-Yun</creator><creator>Young, Ken H.</creator><creator>Xu, Mina L.</creator><creator>Pan, Zenggang</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8623-4067</orcidid><orcidid>https://orcid.org/0000-0002-9012-6680</orcidid><orcidid>https://orcid.org/0000-0001-6754-0480</orcidid><orcidid>https://orcid.org/0000-0003-0217-1789</orcidid><orcidid>https://orcid.org/0000-0002-5755-8932</orcidid><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0001-9513-245X</orcidid></search><sort><creationdate>20221001</creationdate><title>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</title><author>Gisriel, Savanah D. ; Yuan, Ji ; Braunberger, Ryan C. ; Maracaja, Danielle L.V. ; Chen, Xueyan ; Wu, Xiaojun ; McCracken, Jenna ; Chen, Mingyi ; Xie, Yi ; Brown, Laura E. ; Li, Peng ; Zhou, Yi ; Sethi, Tarsheen ; McHenry, Austin ; Hauser, Ronald G. ; Paulson, Nathan ; Tang, Haiming ; Hsi, Eric D. ; Wang, Endi ; Zhang, Qian-Yun ; Young, Ken H. ; Xu, Mina L. ; Pan, Zenggang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-10f893168bab8c875a436aee71ca95906d88ac0d98af4c4d7c7891acbac9f6b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>13/1</topic><topic>13/51</topic><topic>38/32</topic><topic>631/67/1990/291/1621/1915</topic><topic>692/699/1541/1990/291/1621/1915</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>B-cell lymphoma</topic><topic>Case reports</topic><topic>CD20 antigen</topic><topic>Chemotherapy</topic><topic>Effusion</topic><topic>Epstein-Barr virus</topic><topic>Epstein-Barr Virus Infections - complications</topic><topic>Herpesviridae Infections - complications</topic><topic>Herpesvirus 4, Human</topic><topic>Herpesvirus 8, Human</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Laboratory Medicine</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Primary Effusion - diagnosis</topic><topic>Lymphoma, Primary Effusion - pathology</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Myc protein</topic><topic>Pathology</topic><topic>Pax5 protein</topic><topic>Pleural cavity</topic><topic>Primary effusion lymphoma</topic><topic>Retrospective Studies</topic><topic>Rituximab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gisriel, Savanah D.</creatorcontrib><creatorcontrib>Yuan, Ji</creatorcontrib><creatorcontrib>Braunberger, Ryan C.</creatorcontrib><creatorcontrib>Maracaja, Danielle L.V.</creatorcontrib><creatorcontrib>Chen, Xueyan</creatorcontrib><creatorcontrib>Wu, Xiaojun</creatorcontrib><creatorcontrib>McCracken, Jenna</creatorcontrib><creatorcontrib>Chen, Mingyi</creatorcontrib><creatorcontrib>Xie, Yi</creatorcontrib><creatorcontrib>Brown, Laura E.</creatorcontrib><creatorcontrib>Li, Peng</creatorcontrib><creatorcontrib>Zhou, Yi</creatorcontrib><creatorcontrib>Sethi, Tarsheen</creatorcontrib><creatorcontrib>McHenry, Austin</creatorcontrib><creatorcontrib>Hauser, Ronald G.</creatorcontrib><creatorcontrib>Paulson, Nathan</creatorcontrib><creatorcontrib>Tang, Haiming</creatorcontrib><creatorcontrib>Hsi, Eric D.</creatorcontrib><creatorcontrib>Wang, Endi</creatorcontrib><creatorcontrib>Zhang, Qian-Yun</creatorcontrib><creatorcontrib>Young, Ken H.</creatorcontrib><creatorcontrib>Xu, Mina L.</creatorcontrib><creatorcontrib>Pan, Zenggang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gisriel, Savanah D.</au><au>Yuan, Ji</au><au>Braunberger, Ryan C.</au><au>Maracaja, Danielle L.V.</au><au>Chen, Xueyan</au><au>Wu, Xiaojun</au><au>McCracken, Jenna</au><au>Chen, Mingyi</au><au>Xie, Yi</au><au>Brown, Laura E.</au><au>Li, Peng</au><au>Zhou, Yi</au><au>Sethi, Tarsheen</au><au>McHenry, Austin</au><au>Hauser, Ronald G.</au><au>Paulson, Nathan</au><au>Tang, Haiming</au><au>Hsi, Eric D.</au><au>Wang, Endi</au><au>Zhang, Qian-Yun</au><au>Young, Ken H.</au><au>Xu, Mina L.</au><au>Pan, Zenggang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>35</volume><issue>10</issue><spage>1411</spage><epage>1422</epage><pages>1411-1422</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>Rare cases of human herpesvirus 8 (HHV8)-negative effusion-based large B-cell lymphoma (EB-LBCL) occur in body cavities without antecedent or concurrent solid mass formation. In contrast to HHV8 + primary effusion lymphoma (PEL), EB-LBCL has no known association with HIV or HHV8 infection. However, the small sample sizes of case reports and series worldwide, especially from non-Japanese regions, have precluded diagnostic uniformity. Therefore, we conducted a retrospective, multi-institutional study of 55 cases of EB-LBCL and performed a comprehensive review of an additional 147 cases from the literature to identify distinct clinicopathologic characteristics. In our study, EB-LBCL primarily affected elderly (median age 80 years), immunocompetent patients and manifested as lymphomatous effusion without a solid component. The lymphomatous effusions mostly occurred in the pleural cavity (40/55, 73%), followed by the pericardial cavity (17/55, 31%). EB-LBCL expressed CD20 (53/54, 98%) and PAX5 (23/23, 100%). Most cases (30/36, 83%) were of non-germinal center B-cell subtype per the Hans algorithm. HHV8 infection was absent (0/55, 0%), while Epstein-Barr virus was detected in 6% (3/47). Clinically, some patients were managed with drainage alone (15/34, 44%), while others received rituximab alone (4/34, 12%) or chemotherapy (15/34, 44%). Eventually, 56% (22/39) died with a median overall survival (OS) of 14.9 months. Our findings were similar to those from the literature; however, compared to the non-Japanese cases, the Japanese cases had a significantly higher incidence of pericardial involvement, a higher rate of chemotherapy administration, and longer median OS. Particularly, we have found that Japanese residence, presence of pericardial effusion, and absence of MYC rearrangement are all favorable prognostic factors. Our data suggest that EB-LBCL portends a worse prognosis than previously reported, although select patients may be managed conservatively. Overall, EB-LBCL has distinct clinicopathologic characteristics, necessitating the establishment of separate diagnostic criteria and consensus nomenclature.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>35562413</pmid><doi>10.1038/s41379-022-01091-x</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-8623-4067</orcidid><orcidid>https://orcid.org/0000-0002-9012-6680</orcidid><orcidid>https://orcid.org/0000-0001-6754-0480</orcidid><orcidid>https://orcid.org/0000-0003-0217-1789</orcidid><orcidid>https://orcid.org/0000-0002-5755-8932</orcidid><orcidid>https://orcid.org/0000-0002-7361-7162</orcidid><orcidid>https://orcid.org/0000-0001-9513-245X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0893-3952 |
ispartof | Modern pathology, 2022-10, Vol.35 (10), p.1411-1422 |
issn | 0893-3952 1530-0285 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9926946 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | 13/1 13/51 38/32 631/67/1990/291/1621/1915 692/699/1541/1990/291/1621/1915 Aged Aged, 80 and over B-cell lymphoma Case reports CD20 antigen Chemotherapy Effusion Epstein-Barr virus Epstein-Barr Virus Infections - complications Herpesviridae Infections - complications Herpesvirus 4, Human Herpesvirus 8, Human HIV Human immunodeficiency virus Humans Laboratory Medicine Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Primary Effusion - diagnosis Lymphoma, Primary Effusion - pathology Medical prognosis Medicine Medicine & Public Health Myc protein Pathology Pax5 protein Pleural cavity Primary effusion lymphoma Retrospective Studies Rituximab Targeted cancer therapy |
title | Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T18%3A11%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20herpesvirus%208-negative%20effusion-based%20large%20B-cell%20lymphoma:%20a%20distinct%20entity%20with%20unique%20clinicopathologic%20characteristics&rft.jtitle=Modern%20pathology&rft.au=Gisriel,%20Savanah%20D.&rft.date=2022-10-01&rft.volume=35&rft.issue=10&rft.spage=1411&rft.epage=1422&rft.pages=1411-1422&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1038/s41379-022-01091-x&rft_dat=%3Cproquest_pubme%3E2664806804%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718480784&rft_id=info:pmid/35562413&rft_els_id=S0893395222002563&rfr_iscdi=true |